Immunogenicity and safety of a dengue vaccine given as a booster in Singapore: a randomized Phase II, placebo-controlled trial evaluating its effects 5?6 years after completion of the primary series
10.1080/21645515.2019.1661204
Saved in:
Main Authors: | Eujung Juliana Park, Sophia Archuleta, May-Lin Helen Oh, Lynette P Shek, Jing Jin, Matthew Bonaparte, Carina Fargo, Alain Bouckenooghe |
---|---|
Other Authors: | MEDICINE |
Format: | Article |
Published: |
Taylor & Francis
2020
|
Online Access: | https://scholarbank.nus.edu.sg/handle/10635/167996 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Similar Items
-
Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized Phase II, placebo-controlled trial
by: Eujung Juliana Park, et al.
Published: (2021) -
Evaluation of the Safety and Immunogenicity of Fractional Intradermal COVID-19 Vaccines as a Booster: A Pilot Study
by: Niyomnaitham S.
Published: (2023) -
Long-term immunogenicity and safety of tetravalent dengue vaccine (CYD-TDV) in healthy populations in Singapore and Vietnam: 4-year follow-up of randomized, controlled, Phase II trials
by: Ngoc Huu Tran, et al.
Published: (2019) -
Matrix completion from any given set of observations
by: Lee, Troy, et al.
Published: (2014) -
Immunogenicity and reactogenicity of a reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine as a single-dose booster in Singaporean adults
by: Chan, S.H., et al.
Published: (2014)